Zhejiang University: Leukemia trials

The registry lists 14 Leukemia studies with Zhejiang University as lead sponsor. 11 are open to participants now and 0 have results posted.

Early Phase 1 10Phase 1 1Phase 2 2No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic LeukemiaRecruitingNCT07429461Early Phase 1
• Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic LeukemiaRecruitingNCT06793241Early Phase 1
• A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT06762132Early Phase 1
• A Retrospective Study on the Relationship Between Donor Leukocyte Telomere Length and Prognosis of Acute Leukemia Patients Treated With Allogeneic Hematopoietic Stem Cell TransplantationRecruitingNCT06076226
• NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid LeukemiaNot yet recruitingNCT04658004Early Phase 1
• CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's LymphomaNot yet recruitingNCT04609241Early Phase 1
• CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological MalignanciesRecruitingNCT04603872Early Phase 1
• IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid LeukemiaNot yet recruitingNCT04599543Early Phase 1
• A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological MalignanciesRecruitingNCT04532281Early Phase 1
• A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHLRecruitingNCT04532268Early Phase 1
• A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological MalignanciesRecruitingNCT04532203Early Phase 1
• Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALLCompletedNCT04788472Phase 2
• Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALLStatus unknownNCT04740203Phase 1/2
• Decitabine+Cladribine+Cytarabine+Granulocyte Colony-stimulating Factor (D-CLAG) for Relapsed or Refractory Acute Myeloid Leukemia (AML)Status unknownNCT04373395Not applicable